AKT1 and non-small cell lung carcinoma: Further, treatment with pemetrexed, the first line therapy approved for metastatic or advanced NSCLC, led to the arrest in the S phase of the cell cycle and induction of apoptosis via deregulated activation of the Akt pathway in A549 lung cancer cells [65].